---
title: Press Releases | Orasis Pharmaceuticals | Orasis Pharmaceuticals
image: https://orasis-pharma.com/hubfs/raw_assets/public/orasis-website/images/home-hero-bg.jpg
---
[Skip to content](https://orasis-pharma.com/press-releases/author/orasis-pharmaceuticals#main-content)
[ ](https://orasis-pharma.com)
- [ About ](https://orasis-pharma.com/about)
#### [Company Overview Our mission, vision, and story](https://orasis-pharma.com/about)
#### [Leadership Team Meet the executives driving our vision](https://orasis-pharma.com/leadership)
#### [Board of Directors Guidance from industry leaders](https://orasis-pharma.com/board)
#### [Investors Our partners in innovation](https://orasis-pharma.com/investors)
- [ Qlosi ](https://orasis-pharma.com/qlosi)
- [ Presbyopia ](https://orasis-pharma.com/presbyopia)
- News
[Press Releases](https://orasis-pharma.com/press-releases) [In the Media](https://orasis-pharma.com/in-the-media)
- [Contact](https://orasis-pharma.com/contact)
[Qlosi.com](https://qlosi.com)
# Press Releases
All
2026
2025
2024
2023
## 2026
Jul 20, 2026
### [Orasis Pharmaceuticals Doubles Down on Eye Care Professionals, Not Telehealth, as QLOSI® Refills Reach 49.1%](https://orasis-pharma.com/press-releases/orasis-pharmaceuticals-doubles-down-on-eye-care-professionals-not-telehealth-as-qlosi-refills-reach-491)
[Read More](https://orasis-pharma.com/press-releases/orasis-pharmaceuticals-doubles-down-on-eye-care-professionals-not-telehealth-as-qlosi-refills-reach-491)
Jul 15, 2026
### [Orasis Pharmaceuticals Announces Australia Submission of a New Drug Application for BESKA for the Treatment of Presbyopia](https://orasis-pharma.com/press-releases/orasis-pharmaceuticals-announces-australia-submission-of-a-new-drug-application-for-beska-for-the-treatment-of-presbyopia)
[Read More](https://orasis-pharma.com/press-releases/orasis-pharmaceuticals-announces-australia-submission-of-a-new-drug-application-for-beska-for-the-treatment-of-presbyopia)
Jan 27, 2026
### [New Data Demonstrate Qlosi™ Is Pupil Selective With Ciliary Muscle Movement No Different Than A Balanced Salt Solution (BSS) Control](https://orasis-pharma.com/press-releases/new-data-demonstrate-qlosi-is-pupil-selective-with-ciliary-muscle-movement-no-different-than-a-balanced-salt-solution-bss-control)
[Read More](https://orasis-pharma.com/press-releases/new-data-demonstrate-qlosi-is-pupil-selective-with-ciliary-muscle-movement-no-different-than-a-balanced-salt-solution-bss-control)
## 2025
Nov 13, 2025
### [Orasis Pharmaceuticals Expands Access To Qlosi™ With New Starter Packs For Eye Care Professionals, Bolstering Commercial Rollout](https://orasis-pharma.com/press-releases/orasis-pharmaceuticals-expands-access-to-qlosi-with-new-starter-packs-for-eye-care-professionals-bolstering-commercial-rollout)
[Read More](https://orasis-pharma.com/press-releases/orasis-pharmaceuticals-expands-access-to-qlosi-with-new-starter-packs-for-eye-care-professionals-bolstering-commercial-rollout)
Apr 07, 2025
### [Orasis Pharmaceuticals Announces Novel Corrective Eyedrop for Presbyopia, Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4%, Now Available to Prescribe in the U.S.](https://orasis-pharma.com/press-releases/orasis-pharmaceuticals-announces-novel-corrective-eyedrop-presbyopia-qlosi)
[Read More](https://orasis-pharma.com/press-releases/orasis-pharmaceuticals-announces-novel-corrective-eyedrop-presbyopia-qlosi)
## 2024
Oct 16, 2024
### [Orasis Pharmaceuticals Announces Licensing Agreement with Optus Pharmaceuticals for Commercialization of Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4% in Korea](https://orasis-pharma.com/press-releases/orasis-pharmaceuticals-announces-licensing-agreement-with-optus-pharmaceuticals)
[Read More](https://orasis-pharma.com/press-releases/orasis-pharmaceuticals-announces-licensing-agreement-with-optus-pharmaceuticals)
Oct 08, 2024
### [Orasis Pharmaceuticals Completes $78 Million Financing to Support Commercial Launch of Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4%](https://orasis-pharma.com/press-releases/orasis-pharmaceuticals-completes-78-million-financing-to-support-commercial-launch-of-qlosi)
[Read More](https://orasis-pharma.com/press-releases/orasis-pharmaceuticals-completes-78-million-financing-to-support-commercial-launch-of-qlosi)
## 2023
Oct 17, 2023
### [Orasis Pharmaceuticals Announces FDA Approval of QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the Treatment of Presbyopia](https://orasis-pharma.com/press-releases/orasis-pharmaceuticals-announces-fda-approval-of-qlosi-pilocarpine-hydrochloride-ophthalmic-solution-0-4-for-the-treatment-of-presbyopia)
[Read More](https://orasis-pharma.com/press-releases/orasis-pharmaceuticals-announces-fda-approval-of-qlosi-pilocarpine-hydrochloride-ophthalmic-solution-0-4-for-the-treatment-of-presbyopia)
Feb 20, 2023
### [FDA Accepts Orasis Pharmaceuticals’ New Drug Application for CSF-1 for the Treatment of Presbyopia](https://orasis-pharma.com/press-releases/fda-accepts-orasis-pharmaceuticals-new-drug-application-for-csf-1-for-the-treatment-of-presbyopia)
[Read More](https://orasis-pharma.com/press-releases/fda-accepts-orasis-pharmaceuticals-new-drug-application-for-csf-1-for-the-treatment-of-presbyopia)
Jan 03, 2023
### [Orasis Pharmaceuticals Submits New Drug Application for Investigational Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia](https://orasis-pharma.com/press-releases/orasis-pharmaceuticals-submits-new-drug-application-for-investigational-novel-eye-drop-candidate-csf-1-for-the-treatment-of-presbyopia)
[Read More](https://orasis-pharma.com/press-releases/orasis-pharmaceuticals-submits-new-drug-application-for-investigational-novel-eye-drop-candidate-csf-1-for-the-treatment-of-presbyopia)
[ ](https://orasis-pharma.com/)
An ophthalmic pharmaceutical company delivering solutions to reshape vision possibilities.
#### Company
[Company Overview](https://orasis-pharma.com/about) [Leadership Team](https://orasis-pharma.com/leadership) [Board of Directors](https://orasis-pharma.com/board) [Investors](https://orasis-pharma.com/investors)
#### Product
[About Qlosi](https://orasis-pharma.com/qlosi) [About Presbyopia](https://orasis-pharma.com/presbyopia) [Qlosi.com](https://qlosi.com)
#### News & Contact
[Press Releases](https://orasis-pharma.com/press-releases) [In the Media](https://orasis-pharma.com/in-the-media) [Contact Us](https://orasis-pharma.com/contact) [info@orasis-pharma.com](mailto:info@orasis-pharma.com)
©2026 Orasis Pharmaceuticals, Inc. All Rights Reserved. QLOSI®, Orasis Pharmaceuticals, the Orasis Pharmaceuticals logo, and certain other trademarks herein are trademarks of Orasis Pharmaceuticals, Inc.
[Privacy Policy](https://orasis-pharma.com/privacy-policy) [Terms of Service](https://orasis-pharma.com/terms-of-service) [Health Data Privacy](https://orasis-pharma.com/health-data-privacy-policy)
```json
{
"@context" : "https://schema.org",
"@id" : "https://www.orasis-pharma.com/#organization",
"@type" : "Organization",
"address" : {
"@type" : "PostalAddress",
"addressCountry" : "US",
"addressLocality" : "Ponte Vedra",
"addressRegion" : "FL",
"postalCode" : "32081",
"streetAddress" : "203 Fort Wade Rd., #140"
},
"contactPoint" : {
"@type" : "ContactPoint",
"contactType" : "customer service",
"email" : "info@orasis-pharma.com",
"telephone" : "+1-866-672-7471"
},
"description" : "Orasis Pharmaceuticals is an ophthalmic pharmaceutical company delivering solutions to reshape vision possibilities, developer of Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia in adults.",
"logo" : "https://qlosiecp.com/hubfs/HQ%20Only/Orasis_Pharmaceuticals_Logo_RGB.svg",
"name" : "Orasis Pharmaceuticals",
"sameAs" : [ "https://www.linkedin.com/company/orasis-pharmaceuticals/", "https://twitter.com/OrasisPharma" ],
"url" : "https://www.orasis-pharma.com/"
}
```
```json
{
"@context" : "https://schema.org",
"@id" : "https://www.orasis-pharma.com/#website",
"@type" : "WebSite",
"name" : "Orasis Pharmaceuticals",
"publisher" : {
"@id" : "https://www.orasis-pharma.com/#organization"
},
"url" : "https://www.orasis-pharma.com/"
}
```